Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.

7/23/24 7:59:52 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $MESO alert in real time by email

Get the next $MESO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MESO

Date	Price Target	Rating	Analyst
9/24/2024	$12.00	Hold → Buy	Maxim Group
8/29/2024		Hold → Buy	Jefferies
7/23/2024	$4.00 → $11.00	Neutral → Overweight	Piper Sandler
8/31/2023		Hold → Buy	Jefferies
8/7/2023		Buy → Hold	Maxim Group
8/4/2023	$7.00 → $2.00	Overweight → Neutral	Piper Sandler
8/4/2023		Outperform → Mkt Perform	William Blair
3/9/2023	$8.00	Outperform	William Blair

More analyst ratings

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "We have had an extremely busy and productive quarter starting right from the outset with the filing of our Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). We continue to be engaged in active and ongoi
10/30/24 7:11:14 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George ("Investor") for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approval by the United States Food and Drug Administration (FDA) of Mesoblast's lead product candidate Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast's option and will enable the Company to se
9/29/24 8:55:36 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
9/4/24 8:00:00 AM ET
$AVTX
$DRRX
$HALO
$MESO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)
8/28/24 7:27:43 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref
2/28/24 5:57:09 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B
8/30/23 7:07:02 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
9/4/24 8:00:00 AM ET
$AVTX
$DRRX
$HALO
$MESO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ:MESO). Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association
7/5/23 8:30:00 AM ET
$COYA
$MESO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Jane Bell Joins Mesoblast Board
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestments. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms Bell curre
8/18/22 7:00:00 AM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Piper Sandler Upgrades Mesoblast to Overweight, Raises Price Target to $11
Piper Sandler analyst Edward Tenthoff upgrades Mesoblast (NASDAQ:MESO) from Neutral to Overweight and raises the price target from $4 to $11.
7/23/24 1:56:14 PM ET
$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
7/23/24 1:21:51 PM ET
$ADIL
$AEVA
$AOS
$AROC
Biotechnology: Pharmaceutical Preparations
Health Care
Auto Parts:O.E.M.
Consumer Discretionary
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
7/23/24 11:04:22 AM ET
$BEAM
$BRO
$CCK
$DHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Specialty Insurers
Finance

Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.

Chat with this insight

Recent Analyst Ratings for
$MESO

$MESO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

SEC Form SC 13G/A filed by Mesoblast Limited (Amendment)

$MESO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Mesoblast upgraded by Maxim Group with a new price target

Mesoblast upgraded by Jefferies

Mesoblast upgraded by Piper Sandler with a new price target

$MESO
SEC Filings

SEC Form 6-K filed by Mesoblast Limited

SEC Form 6-K filed by Mesoblast Limited

SEC Form 6-K filed by Mesoblast Limited

$MESO
Press Releases

Fastest customizable press release news feed in the world

$MESO
Financials

Live finance-specific insights

$MESO
Leadership Updates

Live Leadership Updates

$MESO
Market Insights

Live Market Insights

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner

Jane Bell Joins Mesoblast Board

Piper Sandler Upgrades Mesoblast to Overweight, Raises Price Target to $11

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.

Chat with this insight

Recent Analyst Ratings for $MESO

$MESO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

SEC Form SC 13G/A filed by Mesoblast Limited (Amendment)

$MESO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Mesoblast upgraded by Maxim Group with a new price target

Mesoblast upgraded by Jefferies

Mesoblast upgraded by Piper Sandler with a new price target

$MESO SEC Filings

SEC Form 6-K filed by Mesoblast Limited

SEC Form 6-K filed by Mesoblast Limited

SEC Form 6-K filed by Mesoblast Limited

$MESO Press Releases

Fastest customizable press release news feed in the world

$MESO Financials

Live finance-specific insights

$MESO Leadership Updates

Live Leadership Updates

$MESO Market Insights

Live Market Insights

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner

Jane Bell Joins Mesoblast Board

Piper Sandler Upgrades Mesoblast to Overweight, Raises Price Target to $11

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

Recent Analyst Ratings for
$MESO

$MESO
Large Ownership Changes

$MESO
Analyst Ratings

$MESO
SEC Filings

$MESO
Press Releases

$MESO
Financials

$MESO
Leadership Updates

$MESO
Market Insights